Cargando…
Development of personalized treatments in lung cancer: focusing on the EGFR mutations and beyond
Lung cancers with epidermal growth factor receptor (EGFR) gene mutation account for ∼40% of adenocarcinoma in East Asians and ∼15% of that in Caucasians, which makes them one of the most common molecularly defined lung cancer subsets. The role of EGFR mutation as a strong predictive biomarker of res...
Autores principales: | Suda, Kenichi, Mitsudomi, Tetsuya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217442/ https://www.ncbi.nlm.nih.gov/pubmed/28210134 http://dx.doi.org/10.2147/LCTT.S49603 |
Ejemplares similares
-
Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with EGFR Mutations
por: Suda, Kenichi, et al.
Publicado: (2021) -
Lung Cancer with MET exon 14 Skipping Mutation: Genetic Feature, Current Treatments, and Future Challenges
por: Fujino, Toshio, et al.
Publicado: (2021) -
Cell Line Models for Acquired Resistance to First-Line Osimertinib in Lung Cancers—Applications and Limitations
por: Ohara, Shuta, et al.
Publicado: (2021) -
Utility of the Ba/F3 cell system for exploring on‐target mechanisms of resistance to targeted therapies for lung cancer
por: Koga, Takamasa, et al.
Publicado: (2022) -
Performance of Ultra-Rapid Idylla™ EGFR Mutation Test in Non-Small-Cell Lung Cancer and Its Potential at Clinical Molecular Screening
por: Suda, Kenichi, et al.
Publicado: (2023)